TAKEDA AND GALAXY BIOTECH SIGN LICENSE AGREEMENT FOR GALAXY'S INVESTIGATIONAL ANTIBODIES FOR THE TREATMENT OF CANCER

Takeda Pharmaceutical Company Limited ("Takeda") and Galaxy Biotech, LLC ("Galaxy") announced that on July 1, both parties have entered into an agreement for the development and marketing of HuL2G7, a humanized anti-Hepatocyte Growth Factor (HGF) monoclonal antibody created by Galaxy.
PipelineReview